Pfizer Executives

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Trending

Pfizer employes about 88.3 K people. The company is managed by 39 executives with total tenure of roughly 179 years, averaging almost 4.0 years of service per executive having 2264.1 employees per reported executive. Evaluation of Pfizer management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Pfizer Inc future performance. Please check Your Equity Center.

Search Insiders

 
Refresh
  John Young  President
Group President - Pfizer Innovative Health and Angela Hwang

  Return on Sales

Pfizer Management Team Effectiveness

Pfizer Inc has Return on Asset of 0.0828 % which means that on every $100 spent on asset it made $0.0828 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 20.94 % implying that it generated $20.94 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 11.02, whereas Return on Average Assets are expected to decline to 0.0008. Pfizer Tax Assets are expected to significantly decrease based on the last few years of reporting. The last year's Tax Assets were at 5.44 Billion. The current year Revenue to Assets is expected to grow to 0.35, whereas Assets Non Current are expected to decline to about 124.2 B. Pfizer Tax Liabilities is expected to significantly decrease based on the last few years of reporting. The last year's Tax Liabilities was at 18.68 BillionThe current year Weighted Average Shares Diluted is expected to grow to about 6.9 B, whereas Weighted Average Shares is expected to decline to about 5.5 B.

  Pfizer Quarterly Total Assets

Pfizer Workforce Comparison

Pfizer Inc is rated below average in number of employees category among related companies. The total workforce of Drug Manufacturers?General industry is at this time estimated at about 231,196. Pfizer totals roughly 88,300 in number of employees claiming about 38% of equities under Drug Manufacturers?General industry.

Pfizer Profit Margins

The company has Net Profit Margin of 0.26 % which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 41.99 % which entails that for every 100 dollars of revenue it generated 0.42 of operating income.

Pfizer Insider Trading

Pfizer Inc Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Pfizer Inc Price Series Summation is a cross summation of Pfizer price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Pfizer Stakeholders

Ian Read Chairman, CEO and Chairman of Executive Committee
John Young Group President - Pfizer Innovative Health and Angela Hwang
Frank DAmelio Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler Executive Vice President General Counsel
Dawn Rogers Chief Human Resource Officer, Executive Vice President
Mikael Dolsten Chief Scientific Officer, President - Worldwide Research, Development and Medical
Lidia Fonseca Executive Vice President, Chief Technology Officer and Digital Officer
Alexander Mackenzie Executive Vice President Chief Development Officer
Geno Germano Group President of Global Innovative Pharma Bus.
Laurie Olson Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna Executive Vice President and Presidentident - Pfizer Global Supply
Freda LewisHall Executive Vice President Chief Medical Officer
Rady Johnson Chief Compliance, Quality and Risk Officer, Executive Vice President
Charles Hill Executive Vice President - Worldwide Human Resources
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang Group President, Pfizer Biopharmaceuticals Group
Kathrin Jansen Senior Vice President - Vaccine Research & Development
Michael Goettler Group President - Pfizer Upjohn
Helen Hobbs Independent Director
Shantanu Narayen Lead Independent Director
James Smith Independent Director
Dennis Ausiello Independent Director
Frances Fergusson Independent Director
Stephen Sanger Independent Director
Wyllie Cornwell Independent Director
Suzanne Johnson Independent Director
Susan Hockfield Independent Director
Dan Littman Independent Director
James Kilts Independent Director
Don Cornwell Independent Director
James Quincey Independent Director
Joseph Echevarria Independent Director
Scott Gottlieb Independent Director
Ronald Blaylock Independent Director
Jennifer Damico Senior Vice President Principal Accounting Officer, Controller
Susan DesmondHellmann Director
Gordon Loh Senior Vice President Corporate Audit

About Pfizer Management Performance

The success or failure of an entity such as Pfizer Inc often depends on how effective the management is. Pfizer management team is responsible for propelling the future growth in the right direction and for administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pfizer management before purchasing its stock. It's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pfizer management is utilizing all available resources in the best possible way? Also, how well is the company doing, relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity. Please read more on our stock advisor page.
Last ReportedProjected for 2020
Return on Investment 9.38  11.02 
Return on Average Assets 9.96  0.0008 
Return on Average Equity 25.72  0.21 
Return on Invested Capital 0.21  0.19 
Return on Sales 0.34  0.33 
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.

Pfizer Manpower Efficiency

Return on Pfizer Manpower

Revenue Per Employee655.7 K
Revenue Per Executive1.4 B
Net Income Per Employee156.6 K
Net Income Per Executive415.6 M
Working Capital Per Employee163.1 K
Working Capital Per Executive369.4 M

Per Employee

Pfizer Per Employee Growth Over Time

  Net Income Per Employee

  Revenue Per Employee

Please check Your Equity Center. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page